Literature DB >> 19496690

Electrophysiologic and immunopathologic correlates in Guillain-Barré syndrome subtypes.

Antonino Uncini1, Nobuhiro Yuki.   

Abstract

Guillain-Barré syndrome (GBS) includes demyelinating and axonal subtypes with different immunopathologic mechanisms. In acute inflammatory demyelinating polyradiculoneuropathy, segmental demyelination and conduction block are the pathological and electrophysiological correlates of muscle weakness. Slowed conductions and increased temporal dispersion of motor responses are more characteristic of the remyelinative phase and do not affect muscle power. In acute motor axonal neuropathy, muscle weakness has been correlated with an antibody-mediated primary axonal degeneration. Conduction block that recovers without development of increased temporal dispersion or other demyelinating features, however, has been described in some patients with antiganglioside antibodies and related to a physiologic conduction block at the axolemma of the Ranvier node. Severity of axonal damage induced by antiganglioside antibodies may vary from reversible functional impairment of nodal axolemma to complete axonal damage with subsequent Wallerian degeneration. In early GBS, current electrophysiologic criteria are unable to distinguish with certainty different subtypes. Serial electrophysiologic studies are mandatory for identification of GBS subtypes and to elucidate the pathophysiologic mechanisms of muscle weakness among demyelination, axonal degeneration and physiologic conduction block.

Entities:  

Mesh:

Year:  2009        PMID: 19496690     DOI: 10.1586/ern.09.43

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  10 in total

Review 1.  On the structural elucidation of GalNAc-GD1a.

Authors:  Yu-Teh Li
Journal:  Neurochem Res       Date:  2012-01-17       Impact factor: 3.996

2.  Outcome of Guillain-Barre syndrome patients with respiratory paralysis.

Authors:  J Kalita; A Ranjan; U K Misra
Journal:  QJM       Date:  2015-10-15

3.  A new approach to ELISA-based anti-glycolipid antibody evaluation of highly adhesive serum samples.

Authors:  Seigo Usuki; Dawn O'Brien; Michael H Rivner; Robert K Yu
Journal:  J Immunol Methods       Date:  2014-05-23       Impact factor: 2.303

4.  Acute Motor Conduction Block Neuropathy: Another Distinct Variant of Guillain-Barre Syndrome.

Authors:  Nilüfer Erdoğmuş Ince; M Fevzi Öztekin; Neşe Öztekin
Journal:  Noro Psikiyatr Ars       Date:  2014-03-01       Impact factor: 1.339

Review 5.  Transient immunosuppression: a bridge between infection and the atypical autoimmunity of Guillain-Barré syndrome?

Authors:  I Steiner; G Rosenberg; I Wirguin
Journal:  Clin Exp Immunol       Date:  2010-10       Impact factor: 4.330

6.  [Association of motor nerve conduction block with different subtypes of childhood Guillain-Barré syndrome].

Authors:  Rui-Di Sun; Jun Jiang; Zhi-Sheng Liu
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2020-09

7.  Clinical and pharmacological aspects of inflammatory demyelinating diseases in childhood: an update.

Authors:  Alberto Spalice; Pasquale Parisi; Laura Papetti; Francesco Nicita; Fabiana Ursitti; Francesca Del Balzo; Enrico Properzi; Alberto Verrotti; Martino Ruggieri; Paola Iannetti
Journal:  Curr Neuropharmacol       Date:  2010-06       Impact factor: 7.363

8.  Motor Nerve Conduction Block Predicting Outcome of Guillain-Barre Syndrome.

Authors:  Jingwen Niu; Mingsheng Liu; Qing Sun; Yi Li; Shuang Wu; Qingyun Ding; Yuzhou Guan; Liying Cui
Journal:  Front Neurol       Date:  2018-06-01       Impact factor: 4.003

9.  Non-COVID Neurological Emergencies: A Silent Killer Going Unnoticed during COVID-19 Pandemic.

Authors:  Nikita Dhar; Govind Madhaw; Mritunjai Kumar; Niraj Kumar; Ashutosh Tiwari; Vinayak Jatale
Journal:  J Neurosci Rural Pract       Date:  2021-02-22

Review 10.  Guillain-Barré syndrome and anti-ganglioside antibodies: a clinician-scientist's journey.

Authors:  Nobuhiro Yuki
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2012       Impact factor: 3.493

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.